Stock chart
Analyses on Hadasit BIO-M (3)
- March 12, 2026March 12, 2026
- Follow-up
SelCure vs. Lineage: Is There an Off-Balance-Sheet Asset Here, or Just Hard-to-Monetize Optionality?
The SelCure thread is economically real, but it still behaves like litigation-backed optionality rather than an accessible off-balance-sheet asset. As long as Hadassit Bio holds only 5.07% of SelCure, lacks full disclosure on the Roche and Lineage economics, faces a sealed exper…
- Follow-up
The Shell Clock: How Much Time Does Hadassit Bio Really Have to Bring in a New Activity?
Hadassit Bio is no longer defined mainly by the May 2028 preservation-list deadline, but by the gap between liquidity that does not cover 12 months, a bridge loan due in February 2027, and the need to bring in both a real activity and fresh equity at roughly the same time.
Hadassit Bio Holdings in 2025: The Portfolio Is Almost Gone, Leaving a Shell, a Small Cash Balance, and a Lawsuit
By the end of 2025 Hadassit Bio was no longer an active life-sciences portfolio but a public shell with a small cash balance, a bridge loan from a major shareholder, and a legal option around SelCure. The right way to read the company now is through two clocks, funding and shell…
